PD2i Vital Sign
Vicor signed a Collaborative Research and Development Agreement (CRADA) with the United States Army on January 23, 2008. Under this CRADA, the U.S. Army, through the United States Army Institute of Surgical Research (USAISR), is exploring ways to assess the severity of injury, and probability of survival, of critically injured combat casualties and critically ill civilian patients. The intention is for the medical personnel at USAISR, in conjunction with our personnel, to test the Company’s PD2i algorithm in several diverse cohorts of animals as well as in human trauma patients, ICU patients and combat casualties. It is our mutual expectation that deterioration in status due to trauma and/or hemorrhage will lead to dimensional reductions reflected by the PD2i value. As of March 31, 2008, two experiments have been completed under this CRADA. As the work with USAISR progresses, we are planning to discuss with the Food and Drug Administration the 510(k) approval for the military application, as well as the use of PD2i in civilian trauma and emergency response utilizing clinical data already obtained by USAISR.